Nebest

Quick links to important sections

Nebest

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nebest

Property Description
Active ingredient Nebivolol
Form Tablet (Oral preparation)
Pharmacological class Beta-blocker (beta1-selective)
General purpose Cardiovascular strain management
Origin Synthetic chemical entity

Nebest is a specialized, prescription-only medicine (POM) whose active ingredient is the synthetic chemical entity Nebivolol. It is clinically recognized as a beta-blocker, a drug class commonly utilized to manage cardiovascular conditions. Its primary function is to reduce the workload on the heart and circulatory system by modulating the activity of the sympathetic nervous system.

What Type of Medicine is Nebest?

Nebest contains Nebivolol, which is categorized as a third-generation beta-blocker, a classification characterized by its advanced profile compared to older agents. The drug is distinguished by its high cardioselectivity—meaning it preferentially targets receptors in the heart—and its unique property of promoting blood vessel relaxation. This combined mechanism has been established in clinical practice, confirming its comprehensive effect on the cardiovascular system.

Composition and Pharmaceutical Form

The core of the preparation is the active substance Nebivolol, which is a single-ingredient product existing as a racemic mixture of the D- and L-isomers. Nebest is presented as an oral preparation in the form of a tablet for ingestion. The precise solid pharmaceutical excipients utilized in the tablet form ensure a stable and consistent delivery of the active compound, facilitating reliable effects upon ingestion.

What is Nebest Generally Used to Manage?

The general purpose of this medication is to provide supportive therapy for cardiovascular health by decreasing strain on the heart muscle and improving efficiency within the circulatory system. The dual action of gently slowing the heart rate while simultaneously enhancing the flexibility and openness of blood vessels, a process known as vasodilation, facilitates easier and more effective systemic blood flow. This collective action assists the body in managing states of elevated cardiovascular demand, a necessity frequently seen in adults with certain chronic cardiac issues.

Regulatory References

  1. Public Assessment Report on Nebivolol ARX 5 mg tablets

What side effects are possible with Nebest?

Possible Side Effects and Safety Information

The official safety information for Nebest, as documented by government regulatory agencies, details potential side effects based on their frequency of occurrence and the body system affected (System Organ Class).

Adverse Reaction Scope

Classification Examples of Documented Reactions
Common (ge 1/100 to <1/10) Headache, dizziness, fatigue, tingling sensation (paresthesia), diarrhea, constipation, nausea, swelling (edema)
Uncommon (ge 1/1,000 to <1/100) Slowed heartbeat (bradycardia), certain heart rhythm disturbances, low blood pressure (hypotension), breathing difficulties (bronchospasm), indigestion, rash, itching, vision disturbances, impotence
Rare (ge 1/10,000 to <1/1,000) Fainting, worsening of psoriasis, dry eyes
Very Rare (<1/10,000) Angioedema (swelling beneath the skin), heart block

Clinically Significant Safety Information

  • Serious Adverse Reactions: Documented serious reactions include angioedema, heart block, severe bradycardia, and cardiogenic shock.
  • Discontinuation Warning: Therapy must not be stopped suddenly. Abrupt cessation is explicitly associated with the risk of exacerbating angina pectoris or precipitating a myocardial infarction (heart attack). A gradual dose reduction is required.
  • Contraindications (Restrictions on Use): The medicine is strictly limited for use in patients with conditions such as severe liver impairment (Child-Pugh Class C), certain severe heart rhythm disorders (e.g., 2 or 3 heart block without a pacemaker), cardiogenic shock, and decompensated heart failure.
  • Population-Specific Caution: Caution is required in patients with pre-existing conditions such as certain circulatory disorders, diabetes mellitus (as symptoms of acute hypoglycemia may be masked), and compensated heart failure, as its use is affected by the status of these conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that there is no clinical experience with an overdose of Nebest (bempedoic acid). Consequently, specific documented overdose presentations, symptom clusters, or dose-related factors have not been established in medical trials.

In the event that an overdosage is suspected, immediate action is required. Because clinical experience is lacking, standard medical protocol is to seek professional guidance right away. The primary instruction found in official drug labeling is to contact Poison Control (1-800-222-1222) for the latest recommendations on how to proceed.

If the individual has collapsed, is experiencing a seizure, has severe difficulty breathing, or cannot be awakened, immediately call emergency medical services (911 in the U.S.). These are signs of a severe medical emergency, which require urgent, life-saving intervention regardless of the cause. Following the steps for emergency response ensures timely access to necessary medical support for overdose management.

Therapeutic Uses of Nebest

Quick Facts: Therapeutic Domains

  • Supports the management of high blood pressure (hypertension).
  • Used to address mild to moderate chronic heart failure in elderly patients (typically those aged 70 years and older), when administered with other standard treatments.
  • Assists in reducing the occurrence of major cardiovascular events, such as heart attack and stroke, in individuals with high blood pressure.

What Nebest Treats: Main Uses and Benefits

Nebest is a prescription medication utilized in cardiovascular care to support several health domains. Its primary therapeutic application is the management of essential hypertension (high blood pressure). Consistent use, as part of a comprehensive treatment plan, assists in achieving and maintaining blood pressure levels within a desirable range. This is a key measure in supporting long-term health and reducing the potential for adverse cardiovascular events.

Nebest is also indicated for the management of mild to moderate chronic heart failure in patients 70 years of age and older, when used in conjunction with other established therapies. In this context, it contributes to supporting cardiac function and may help to address associated symptoms.

Controlling high blood pressure is an important step that helps mitigate the risk of stroke and heart attack in vulnerable populations. The medication is an adjunct to lifestyle and dietary adjustments as part of a full treatment strategy.

Eligibility and Restrictions for Use

Nebest's eligibility rules are strictly defined by regulatory authorities and depend on a patient's pre-existing health conditions and age.

Populations Excluded from Use (Contraindicated)

Nebest is contraindicated and must not be used in individuals with:

  • Severe bradycardia (very slow heart rate), cardiogenic shock, or acute, decompensated heart failure.
  • Second- or third-degree heart block (without a permanent pacemaker) or sick sinus syndrome.
  • Severe hepatic impairment (severe liver function disorder).
  • A history of bronchospasm or bronchial asthma.
  • Metabolic acidosis or untreated pheochromocytoma.

Age and Condition-Based Eligibility

Population Group Eligibility Status (As per Labeling)
Children & Adolescents (le 18 years) Not recommended; safety and efficacy have not been established.
Adults (ge 18 years) Approved for the management of essential hypertension.
Elderly (ge 70 years) Approved for stable mild-to-moderate chronic heart failure (as adjunct therapy).
Severe Renal Impairment Use restricted; requires caution and a lower starting dose due to altered drug clearance.
Pregnancy Use restricted; generally avoided unless the benefit justifies the risk to the fetus.
Lactation (Breastfeeding) Not recommended; Nebest passes into breast milk.

The official eligibility profile separates those with established use, such as adults for hypertension and the elderly for heart failure, from populations where use is medically prohibited (contraindicated) or structurally limited (e.g., organ impairment). Use is restricted when conditions like moderate hepatic impairment or severe renal impairment necessitate specific, cautious initiation of therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Nebivolol, the active ingredient in Nebest, as specified in regulatory documents.

Pharmacokinetic Interactions (Exposure Modification)

Co-administration with inhibitors of the CYP2D6 enzyme system may significantly alter the drug's exposure profile. Regulatory information documents that strong CYP2D6 inhibitors, such as certain antidepressants (e.g., Fluoxetine, Paroxetine), cause a substantial increase in the plasma levels of the active d-nebivolol. Similarly, the drug Cimetidine is documented to increase d-nebivolol exposure by over 20%.

Pharmacodynamic Interactions (Additive Effects)

Interactions involving an additive effect on cardiovascular function are officially noted. Concomitant use with Non-Dihydropyridine Calcium Channel Blockers (e.g., Diltiazem, Verapamil) and Digitalis Glycosides may result in excessive reductions in heart rate and depressed cardiac contractility. Other agents, including Class I Antiarrhythmics, also potentiate effects on atrio-ventricular conduction time.

Interaction Restrictions and Timing Rules

Specific restrictions apply to co-administration. The use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) is documented to potentially reduce the expected antihypertensive efficacy. Furthermore, while Nebivolol absorption is generally not affected by food, antacids containing Aluminum Hydroxide require a separation of administration by at least 2 hours to ensure optimal drug absorption. The interaction profile in individuals classified as CYP2D6 Poor Metabolizers documents substantially increased exposure to d-nebivolol.

Mechanism of Action

Selective Blockade of Cardiac beta1-Receptors

The drug's primary action involves the D-isomer component acting as a selective antagonist at beta1-Adrenergic Receptors on the heart, dampening the sympathetic nervous system's signaling by preventing the binding of catecholamines. This cascade results in both negative chronotropy (slowing the heart rate) and negative inotropy (reducing the force of contractions).


Nitric Oxide (NO)-Mediated Peripheral Vasodilation

The secondary mechanism involves the L-isomer component stimulating beta3-Adrenergic Receptors on the vascular endothelium. This interaction activates the Endothelial Nitric Oxide Synthase (eNOS) enzyme, increasing the local production of Nitric Oxide (NO), a signaling molecule. The resulting cascade leads to peripheral vasodilation—the relaxation and widening of systemic blood vessels—which results in a reduction in Systemic Vascular Resistance (PVR).


Isomer Synergy for Dual Hemodynamic Profile

The overall effect profile arises from the synergy between the drug's two isomers, with one responsible for the cardiac effects and the other for the vascular effects. This complementary action results in the simultaneous reduction of cardiac output (via lowered rate and force) and peripheral resistance, contributing to the drug's dual hemodynamic profile.

Dosage and Administration Information

How to Use Nebest

Nebest is an oral tablet intended for long-term maintenance therapy. The medication is taken once daily and the tablets may be swallowed with a sufficient amount of fluid with or without food. For consistent results, the dose is administered at the same time each day.


Official Dosing Regimens

The standard starting dose for adults with hypertension is 5 mg once daily. This dose may be slowly increased at 2-week intervals up to a maximum daily dose of 40 mg. In contrast, the protocol for stable chronic heart failure in elderly patients (70 years or older) requires a supervised, slow titration period. Treatment begins at 1.25 mg once daily, with the dose gradually doubled at 1 to 2-week intervals, not to exceed the maximum recommended dose of 10 mg. Tablets are often scored to facilitate the precise low doses required for this titration.


Administration Requirements

Specific procedural rules apply to usage and cessation. If a dose is forgotten, the patient must skip the missed dose and take the next dose at the regular scheduled time; a double dose must not be taken. Furthermore, the medicine is not intended for abrupt discontinuation; therapy must be gradually tapered over approximately 1 to 2 weeks when stopping. For patients with moderate hepatic or severe renal impairment, the starting dose is reduced to 2.5 mg once daily, with slow titration.

Recent Clinical Evidence

Research evidence / Overview of studies for Nebest

Evidence Supporting Use in Essential Hypertension

The evidence available for Nebest in the context of essential hypertension (high blood pressure) includes multiple Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over defined time intervals. The typical design involved comparing individuals receiving Nebest against those receiving a placebo or sometimes against those receiving a different type of medicine.

Researchers in these short-term studies, which commonly lasted between 6 and 12 weeks, primarily monitored outcomes related to monitoring physiological strain by measuring changes in both seated systolic and diastolic blood pressure. Studies monitored outcomes related to blood pressure measurements in groups receiving Nebest compared to those receiving placebo. Meta-analyses sometimes explored how the observed measurements compared to outcomes reported in studies of certain other types of medicines.

What remains uncertain is the full extent of the long-term outcomes. While the short-term trials establish measured changes in blood pressure, there is limited information for long-term outcomes derived from RCTs specifically designed to compare Nebest's effect on major cardiovascular events (such as stroke or heart attack) against those of other standard treatments.


Evidence Supporting Use in Mild to Moderate Chronic Heart Failure

The evidence available for Nebest in mild to moderate chronic heart failure (CHF) in older adults includes a single, large-scale, international RCT known as the SENIORS study. This major study was conducted during periods of increased symptom activity in older patients (ge 70 years old) to observe outcomes related to the management of chronic functional imbalance.

Researchers focused on a combined outcome that tracked the time until the first occurrence of either all-cause mortality or hospital admission due to a cardiovascular event. Studies examined how the combined event rate evolved over the study's duration and reported patterns observed in the group receiving Nebest compared to the placebo group over the study's duration, which averaged about 21 months of follow-up.

Evidence relating to the single measure of all-cause mortality was inconclusive in the main trial analysis. The results apply only to the populations studied, meaning data are still emerging regarding the direct application of these findings to younger patients (under age 70) with heart failure. The evidence level is documented for the specific older population that was studied.


Research Gaps and Areas of Uncertainty

Comparative evidence is lacking from large-scale, long-term RCTs that specifically measured Nebest's impact on cardiovascular events against other established treatments. The main heart failure evidence applies strictly to the elderly (70+ years), and there is limited information to draw conclusions about outcomes in younger adults with the same condition. Research also explored use in specific populations, such as African American patients with hypertension, where observed findings describe the measurements of blood pressure and patient-reported outcomes.

Frequently Asked Questions (FAQ)

Common questions about Nebest (FAQ)


Q: How is Nebest different from similar medicines in the same class?

Official information describes the active ingredient in Nebest as a highly selective beta1-blocker. It also has a unique property of promoting vasodilation (blood vessel relaxation) through the nitric oxide pathway. This dual mechanism—affecting both heart rate and blood vessel flexibility—distinguishes its activity profile within the beta-blocker class, which may be different from older agents.


Q: Does Nebest have a common effect on sleep patterns?

According to official safety documents, Nebest may cause changes in sleep patterns. Reactions such as insomnia (trouble sleeping) and nightmares have been reported in the uncommon frequency range. This is a documented effect that has occurred in patients taking Nebest.


Q: How long does Nebest take to start working?

While some reduction in blood pressure may be observed shortly after starting the medicine, the full therapeutic effect can take time. Clinical studies indicate that the maximum benefit in lowering blood pressure may require several weeks to be achieved. It is primarily used for long-term maintenance, and not for treating acute symptoms that require immediate relief.


Q: What should I expect Nebest to feel like when it begins to work?

Nebest is designed to work gradually and often does not cause a noticeable change in sensation. However, common adverse reactions reported during initial use include dizziness and fatigue (tiredness). These feelings are reported reactions that may occur when starting the treatment, and official information suggests they may lessen over time.


Q: Is it okay to drink coffee while taking Nebest?

The official prescribing information does not specifically list coffee as a formal drug interaction. However, general public health advice for patients on antihypertensive medications suggests that excessive consumption of caffeine can potentially counteract the medicine's intended blood pressure-lowering effect.


Q: Is Nebest considered a 'strong' medicine?

Nebest is an established prescription treatment for certain cardiovascular conditions, including high blood pressure and chronic heart failure. Official documents define its suitability by its demonstrated efficacy in clinical trials compared to placebo, and not by a qualitative classification like 'strong' or 'weak.'


Q: Does Nebest have a generic version available?

Yes, the active ingredient in Nebest, Nebivolol, is available as a generic medicine in the United States and other regions. The generic product contains the same active substance, strength, and form as the brand name, and is required by regulatory bodies to demonstrate bioequivalence.


Q: How does Nebest compare to an ACE inhibitor?

Nebest and ACE inhibitors belong to different classes of medication and work through different mechanisms to manage cardiovascular strain. Clinical trials sometimes use both types of agents as part of comprehensive treatment strategies, but regulatory documents do not provide direct comparison statements on their relative effectiveness.


Q: Does Nebest interact with alcohol?

Official prescribing information states that combining Nebest with alcohol may lead to an additive effect in lowering blood pressure. This potential interaction may increase the risk of adverse reactions such as dizziness and fainting. This is an officially noted caution described in the drug's safety information.


Q: What kind of monitoring (like blood tests) is generally needed while taking Nebest?

Official warnings note that the medicine must be used with caution in patients with conditions such as diabetes, kidney (renal) impairment, or liver (hepatic) impairment. These cautions suggest that monitoring related to these specific conditions may be relevant during treatment.


Q: How long does Nebest stay in your system after you stop taking it?

The official label describes the time it takes for the drug concentration to decrease by half, known as its half-life. For most patients, this half-life for Nebivolol is approximately 12 hours. In certain patient groups known as 'poor metabolizers,' this process is slower, and the half-life may be up to 19 hours.


Q: Does Nebest affect fertility?

Nonclinical studies, which use animal models to examine the potential effects of Nebivolol on reproduction, have been documented in the official label. Based on the findings from these specific animal studies, official reports indicate that the studies did not demonstrate adverse effects on fertility at the high doses tested.


Q: Do studies suggest that Nebest works differently in men versus women?

Official sub-analyses from the clinical trial populations have been conducted. These analyses indicate that the measured reduction in blood pressure was not found to differ significantly between men and women. There are, however, known pharmacokinetic differences based on certain metabolic profiles.


Q: What is the difference between the brand name and generic versions of Nebest?

The primary difference is the name and manufacturer. Generic versions contain the identical active ingredient, Nebivolol, in the same strength and dosage form as the brand name product. Regulatory agencies require that generics are bioequivalent, ensuring they work the same way in the body.


Q: Does taking Nebest require any lifestyle changes?

Authoritative public health guidance for managing high blood pressure or heart failure generally recommends lifestyle modifications, such as changes in diet and activity, alongside medication. These changes are broadly recommended for these cardiovascular conditions.


Q: Are the side effects of Nebest generally temporary?

Official documents do not specify the duration for every possible side effect. However, some commonly reported adverse reactions, such as dizziness and fatigue (tiredness), are often observed when initiating treatment. This suggests that these specific effects may lessen or resolve as the body adjusts to the medication.

How should Nebest be stored and disposed of?

How to Store and Dispose of Nebest

Nebest (nebivolol) tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).


Storage Requirements

  • Environmental Protection: The medicine must be kept away from excess heat and moisture and should not be frozen. It is also important to protect the tablets from direct light.
  • Container and Safety: Keep the tablets in the original container, ensuring it is tightly closed. Nebest must be stored securely, out of the sight and reach of children.

Disposal Instructions

Expired or unused Nebest should be disposed of according to local regulations. Authorities generally recommend utilizing a drug take-back program or returning the medicine to a pharmacy. The product must not be thrown into wastewater or drains, as the active ingredient can be toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nebest found in:

A-Z Index: